Why did coapt win while mitra-FR failed? Defining the appropriate patient population for MitraClip

Kimberly Atianzar, Ming Zhang, Zachary Newhart, Sameer Gafoor

Research output: Contribution to journalArticle

4 Citations (Scopus)

Abstract

In 2018, the world of functional mitral regurgitation changed with the presentation of two trials - Multicentre Study of Percutaneous Mitral Valve Repair MitraClip Device in Patients With Severe Secondary Mitral Regurgitation (MITRA-FR) and Cardiovascular Outcomes Assessment of the MitraClip Percutaneous Therapy for Heart Failure Patients with Functional Mitral Regurgitation (COAPT). The trials, which seemed to point in two different directions, raised significant questions for the field. This article looks at the differences in effective regurgitant area, guideline-directed medical therapy, patient selection, technical clues and other reasons why the trials had similar aims but very different findings.

Original languageEnglish (US)
Pages (from-to)45-47
Number of pages3
JournalInterventional Cardiology Review
Volume14
Issue number1
DOIs
StatePublished - Jan 1 2019

Fingerprint

Mitral Valve Insufficiency
Population
Mitral Valve
Patient Selection
Multicenter Studies
Heart Failure
Outcome Assessment (Health Care)
Guidelines
Equipment and Supplies
Therapeutics

Keywords

  • COAPT
  • Congestive heart failure
  • Effective orifice area
  • Functional mitral regurgitation
  • Heart failure
  • MITRA-FR
  • Mitral regurgitation
  • Optimal medical therapy
  • Secondary mitral regurgitation

ASJC Scopus subject areas

  • Cardiology and Cardiovascular Medicine

Cite this

Why did coapt win while mitra-FR failed? Defining the appropriate patient population for MitraClip. / Atianzar, Kimberly; Zhang, Ming; Newhart, Zachary; Gafoor, Sameer.

In: Interventional Cardiology Review, Vol. 14, No. 1, 01.01.2019, p. 45-47.

Research output: Contribution to journalArticle

@article{4188c0d8e70949479cfedc7cb352915b,
title = "Why did coapt win while mitra-FR failed? Defining the appropriate patient population for MitraClip",
abstract = "In 2018, the world of functional mitral regurgitation changed with the presentation of two trials - Multicentre Study of Percutaneous Mitral Valve Repair MitraClip Device in Patients With Severe Secondary Mitral Regurgitation (MITRA-FR) and Cardiovascular Outcomes Assessment of the MitraClip Percutaneous Therapy for Heart Failure Patients with Functional Mitral Regurgitation (COAPT). The trials, which seemed to point in two different directions, raised significant questions for the field. This article looks at the differences in effective regurgitant area, guideline-directed medical therapy, patient selection, technical clues and other reasons why the trials had similar aims but very different findings.",
keywords = "COAPT, Congestive heart failure, Effective orifice area, Functional mitral regurgitation, Heart failure, MITRA-FR, Mitral regurgitation, Optimal medical therapy, Secondary mitral regurgitation",
author = "Kimberly Atianzar and Ming Zhang and Zachary Newhart and Sameer Gafoor",
year = "2019",
month = "1",
day = "1",
doi = "10.15420/icr.2018.40.1",
language = "English (US)",
volume = "14",
pages = "45--47",
journal = "Interventional Cardiology",
issn = "1755-5302",
publisher = "Future Medicine Ltd.",
number = "1",

}

TY - JOUR

T1 - Why did coapt win while mitra-FR failed? Defining the appropriate patient population for MitraClip

AU - Atianzar, Kimberly

AU - Zhang, Ming

AU - Newhart, Zachary

AU - Gafoor, Sameer

PY - 2019/1/1

Y1 - 2019/1/1

N2 - In 2018, the world of functional mitral regurgitation changed with the presentation of two trials - Multicentre Study of Percutaneous Mitral Valve Repair MitraClip Device in Patients With Severe Secondary Mitral Regurgitation (MITRA-FR) and Cardiovascular Outcomes Assessment of the MitraClip Percutaneous Therapy for Heart Failure Patients with Functional Mitral Regurgitation (COAPT). The trials, which seemed to point in two different directions, raised significant questions for the field. This article looks at the differences in effective regurgitant area, guideline-directed medical therapy, patient selection, technical clues and other reasons why the trials had similar aims but very different findings.

AB - In 2018, the world of functional mitral regurgitation changed with the presentation of two trials - Multicentre Study of Percutaneous Mitral Valve Repair MitraClip Device in Patients With Severe Secondary Mitral Regurgitation (MITRA-FR) and Cardiovascular Outcomes Assessment of the MitraClip Percutaneous Therapy for Heart Failure Patients with Functional Mitral Regurgitation (COAPT). The trials, which seemed to point in two different directions, raised significant questions for the field. This article looks at the differences in effective regurgitant area, guideline-directed medical therapy, patient selection, technical clues and other reasons why the trials had similar aims but very different findings.

KW - COAPT

KW - Congestive heart failure

KW - Effective orifice area

KW - Functional mitral regurgitation

KW - Heart failure

KW - MITRA-FR

KW - Mitral regurgitation

KW - Optimal medical therapy

KW - Secondary mitral regurgitation

UR - http://www.scopus.com/inward/record.url?scp=85072266158&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85072266158&partnerID=8YFLogxK

U2 - 10.15420/icr.2018.40.1

DO - 10.15420/icr.2018.40.1

M3 - Article

AN - SCOPUS:85072266158

VL - 14

SP - 45

EP - 47

JO - Interventional Cardiology

JF - Interventional Cardiology

SN - 1755-5302

IS - 1

ER -